Related Experiment Video

Updated: Feb 13, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

14.0K

Treatment of early stage chronic hepatitis C virus infection

Francesca Romana Ponziani1, Luca Miele1, Annalisa Tortora1

  • 1a Internal Medicine, Gastroenterology and Hepatology Unit, Fondazione Policlinico "A. Gemelli" , Catholic University of Rome , Rome , Italy.

Expert Review of Clinical Pharmacology
|March 3, 2018
PubMed

Insights

Treating early-stage Hepatitis C Virus (HCV) infection with direct-acting antivirals (DAAs) offers significant benefits beyond liver health. Early intervention improves extra-hepatic conditions and quality of life, making it a rewarding approach.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacoeconomics

Background:

  • Hepatitis C Virus (HCV) infection is effectively treated with direct-acting antivirals (DAAs), achieving high cure rates.
  • The primary barrier to widespread HCV treatment is the high cost of DAAs.
  • Early-stage treatment of HCV infection is increasingly recognized as a highly beneficial strategy.

Purpose of the Study:

  • To review the advantages of treating chronic HCV infection during its early stages.
  • To assess considerations for initiating HCV treatment in patients with minimal liver disease.
  • To evaluate the impact of viral eradication on extra-hepatic manifestations and quality of life.

Main Methods:

  • Literature review focusing on early-stage HCV treatment benefits.
  • Analysis of HCV-associated conditions affected by viral eradication.
  • Evaluation of pharmaco-economic data related to early HCV treatment.

Main Results:

  • HCV viral eradication in early disease positively impacts lymphoma risk, insulin resistance, glycemic control, and renal function.
  • Early treatment leads to improvements in patients' overall quality of life.
  • Pharmaco-economic analysis supports the cost-effectiveness of early HCV intervention.

Conclusions:

  • Treating HCV in patients with minimal liver disease yields pleiotropic benefits extending beyond liver outcomes.
  • Early HCV treatment is a clinically and economically advantageous strategy.
  • Viral eradication offers a comprehensive approach to managing HCV and its associated comorbidities.
Abstract

Keywords:
HCVLow fibrosisantiviral treatmentextra-hepatic manifestationsoutcomepharmaco-economy

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K
"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

12.2K

Related Concept Videos

Stages of Infection01:26

Stages of Infection

Stages of infection describe what happens to a susceptible host once a pathogen invades the human body. The stages of infection are incubation, prodromal, illness, stage of decline, and convalescence. The incubation stage is the period from exposure to a pathogen until symptoms start. The infected person is unaware of impending illness as the pathogens grow and multiply within the body. The duration may vary depending on the type of infection. The incubation period of measles averages ten to...
65.5K
What are Viruses?00:50

What are Viruses?

Overview
128.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.3K
Stages of Sleep01:22

Stages of Sleep

Sleep progresses through distinct stages, each characterized by specific brain wave patterns and physiological responses ranging from wakefulness to stages of non-rapid eye movement, known as non-REM, to rapid eye movement, referred to as REM. Understanding these stages helps in recognizing how sleep supports various bodily and cognitive functions.
Before sleep begins, in wakefulness, the brain exhibits primarily beta waves, which are high in frequency and low in amplitude, indicating alertness...
1.5K
Stages of General Anesthesia01:22

Stages of General Anesthesia

Various sedation levels offer significant advantages in facilitating procedural interventions for patients undergoing medical or invasive surgical procedures. These levels span from anxiolysis to general anesthesia, providing a spectrum of sedative effects to cater to specific patient needs. Anxiolysis reduces anxiety and is achieved through minimal sedation, enabling patients to remain awake and responsive while feeling more at ease during the procedure. This level can benefit minor...
1.8K